Does EZETIMIBE Cause Malignant neoplasm progression? 14 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Malignant neoplasm progression have been filed in association with EZETIMIBE (Ezetimibe). This represents 0.1% of all adverse event reports for EZETIMIBE.
14
Reports of Malignant neoplasm progression with EZETIMIBE
0.1%
of all EZETIMIBE reports
2
Deaths
10
Hospitalizations
How Dangerous Is Malignant neoplasm progression From EZETIMIBE?
Of the 14 reports, 2 (14.3%) resulted in death, 10 (71.4%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EZETIMIBE. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does EZETIMIBE Cause?
Myalgia (2,066)
Fatigue (876)
Drug ineffective (812)
Arthralgia (766)
Dyspnoea (766)
Nausea (742)
Dizziness (717)
Diarrhoea (688)
Headache (626)
Malaise (591)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which EZETIMIBE Alternatives Have Lower Malignant neoplasm progression Risk?
EZETIMIBE vs EZETIMIBE\ROSUVASTATIN
EZETIMIBE vs EZETIMIBE\SIMVASTATIN
EZETIMIBE vs EZOGABINE
EZETIMIBE vs FACTOR XIII CONCENTRATE
EZETIMIBE vs FAM-TRASTUZUMAB DERUXTECAN-NXKI